Simultaneous determination of L-dopa and 3-O-methyldopa in human platelets and plasma using high-performance liquid chromatography with electrochemical detection

F. Blandini, E. Martignoni, C. Pacchetti, S. Desideri, D. Rivellini, G. Nappi

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Various high-performance liquid chromatographic (HPLC) methods for the determination of plasma levels of L-dopa and of its metabolite, 3-O- methyldopa (3-OMD), have been previously described. In this study, we report a modification of these methods, that enables the assay of these two compounds in platelets and plasma obtained from the same sample of whole blood. Reversed-phase (RP) HPLC with electrochemical (coulometric) detection was used. The within-run and between-run coefficients of variations, for the two compounds, were less than 10%, in both platelets and plasma; the detection limits for platelet levels of L-dopa and 3-OMD were 2 and 6 ng/109 platelets, respectively. In plasma, the detection limits for L-dopa and 3- OMD were 1 and 3 ng/ml, respectively. The method is rapid and simple. When applied to a population of patients with Parkinson's disease under treatment with L-dopa, this method revealed detectable levels of L-dopa and 3-OMD in the platelets of all patients. The application of this technique may provide new insights into the pharmacokinetics of L-dopa in patients with Parkinson's disease.

Original languageEnglish
Pages (from-to)278-282
Number of pages5
JournalJournal of Chromatography B: Biomedical Applications
Volume700
Issue number1-2
DOIs
Publication statusPublished - Oct 24 1997

Fingerprint

High performance liquid chromatography
Levodopa
Platelets
Plasmas
Pharmacokinetics
Liquids
Metabolites
3-O-methyl-DOPA
Assays
Blood

Keywords

  • 3-O-Methyldopa
  • L-Dopa

ASJC Scopus subject areas

  • Chemistry(all)

Cite this

@article{0b6fcad0e4174489ada38689312d8d9e,
title = "Simultaneous determination of L-dopa and 3-O-methyldopa in human platelets and plasma using high-performance liquid chromatography with electrochemical detection",
abstract = "Various high-performance liquid chromatographic (HPLC) methods for the determination of plasma levels of L-dopa and of its metabolite, 3-O- methyldopa (3-OMD), have been previously described. In this study, we report a modification of these methods, that enables the assay of these two compounds in platelets and plasma obtained from the same sample of whole blood. Reversed-phase (RP) HPLC with electrochemical (coulometric) detection was used. The within-run and between-run coefficients of variations, for the two compounds, were less than 10{\%}, in both platelets and plasma; the detection limits for platelet levels of L-dopa and 3-OMD were 2 and 6 ng/109 platelets, respectively. In plasma, the detection limits for L-dopa and 3- OMD were 1 and 3 ng/ml, respectively. The method is rapid and simple. When applied to a population of patients with Parkinson's disease under treatment with L-dopa, this method revealed detectable levels of L-dopa and 3-OMD in the platelets of all patients. The application of this technique may provide new insights into the pharmacokinetics of L-dopa in patients with Parkinson's disease.",
keywords = "3-O-Methyldopa, L-Dopa",
author = "F. Blandini and E. Martignoni and C. Pacchetti and S. Desideri and D. Rivellini and G. Nappi",
year = "1997",
month = "10",
day = "24",
doi = "10.1016/S0378-4347(97)00307-1",
language = "English",
volume = "700",
pages = "278--282",
journal = "Journal of Chromatography B: Biomedical Sciences and Applications",
issn = "1387-2273",
publisher = "Elsevier BV",
number = "1-2",

}

TY - JOUR

T1 - Simultaneous determination of L-dopa and 3-O-methyldopa in human platelets and plasma using high-performance liquid chromatography with electrochemical detection

AU - Blandini, F.

AU - Martignoni, E.

AU - Pacchetti, C.

AU - Desideri, S.

AU - Rivellini, D.

AU - Nappi, G.

PY - 1997/10/24

Y1 - 1997/10/24

N2 - Various high-performance liquid chromatographic (HPLC) methods for the determination of plasma levels of L-dopa and of its metabolite, 3-O- methyldopa (3-OMD), have been previously described. In this study, we report a modification of these methods, that enables the assay of these two compounds in platelets and plasma obtained from the same sample of whole blood. Reversed-phase (RP) HPLC with electrochemical (coulometric) detection was used. The within-run and between-run coefficients of variations, for the two compounds, were less than 10%, in both platelets and plasma; the detection limits for platelet levels of L-dopa and 3-OMD were 2 and 6 ng/109 platelets, respectively. In plasma, the detection limits for L-dopa and 3- OMD were 1 and 3 ng/ml, respectively. The method is rapid and simple. When applied to a population of patients with Parkinson's disease under treatment with L-dopa, this method revealed detectable levels of L-dopa and 3-OMD in the platelets of all patients. The application of this technique may provide new insights into the pharmacokinetics of L-dopa in patients with Parkinson's disease.

AB - Various high-performance liquid chromatographic (HPLC) methods for the determination of plasma levels of L-dopa and of its metabolite, 3-O- methyldopa (3-OMD), have been previously described. In this study, we report a modification of these methods, that enables the assay of these two compounds in platelets and plasma obtained from the same sample of whole blood. Reversed-phase (RP) HPLC with electrochemical (coulometric) detection was used. The within-run and between-run coefficients of variations, for the two compounds, were less than 10%, in both platelets and plasma; the detection limits for platelet levels of L-dopa and 3-OMD were 2 and 6 ng/109 platelets, respectively. In plasma, the detection limits for L-dopa and 3- OMD were 1 and 3 ng/ml, respectively. The method is rapid and simple. When applied to a population of patients with Parkinson's disease under treatment with L-dopa, this method revealed detectable levels of L-dopa and 3-OMD in the platelets of all patients. The application of this technique may provide new insights into the pharmacokinetics of L-dopa in patients with Parkinson's disease.

KW - 3-O-Methyldopa

KW - L-Dopa

UR - http://www.scopus.com/inward/record.url?scp=0030656298&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030656298&partnerID=8YFLogxK

U2 - 10.1016/S0378-4347(97)00307-1

DO - 10.1016/S0378-4347(97)00307-1

M3 - Article

C2 - 9390741

AN - SCOPUS:0030656298

VL - 700

SP - 278

EP - 282

JO - Journal of Chromatography B: Biomedical Sciences and Applications

JF - Journal of Chromatography B: Biomedical Sciences and Applications

SN - 1387-2273

IS - 1-2

ER -